Dr. Schally primary interest includes the development of new therapies for prostatic, breast, colorectal, pancreatic, renal, bladder, brain, ovarian, endometrial, lung, gastric cancer, and other solid cancers as well as for acute myeloid leukemia, based on antagonistic analogs of growth hormone-releasing hormone (GHRH).